Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT06186869)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06186869 Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06186869 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with a BMI of 30 or higher, or a waist measurement greater than 94 cm for men or 80 cm for women, with or without signs of metabolic syndrome
People between 18 and 65 years of age, of any sex
People who have been diagnosed with fat buildup in the liver (hepatic steatosis), confirmed by a specific scan called a FibroScan using a measurement known as CAP above 238 dB/m

Who may not be able to join:

People who are at a normal weight or underweight
People who have other medical conditions that could affect liver fat, including neurological, psychiatric, gastrointestinal, cancer-related, or heart and blood vessel diseases
People who are pregnant or breastfeeding
People who have bone or joint conditions that could prevent them from exercising regularly
People whose level of liver fat cannot be measured using a FibroScan
People who do not hold a valid medical certificate confirming they are fit to take part in non-competitive physical activity

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Endrit Shahini, MD, IRCCS Saverio de Bellis

Phone: 00390804994249

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06186869

Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: 00390804994249

More information: https://clinicaltrials.gov/study/NCT06186869

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with a BMI of 30 or higher, or a waist measurement greater than 94 cm for men or 80 cm for women, with or without signs of metabolic syndrome
People between 18 and 65 years of age, of any sex
People who have been diagnosed with fat buildup in the liver (hepatic steatosis), confirmed by a specific scan called a FibroScan using a measurement known as CAP above 238 dB/m

Who may not be able to join:

People who are at a normal weight or underweight
People who have other medical conditions that could affect liver fat, including neurological, psychiatric, gastrointestinal, cancer-related, or heart and blood vessel diseases
People who are pregnant or breastfeeding
People who have bone or joint conditions that could prevent them from exercising regularly
People whose level of liver fat cannot be measured using a FibroScan
People who do not hold a valid medical certificate confirming they are fit to take part in non-competitive physical activity

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Registry

ClinicalTrials.gov

Start date

2 October 2023

Est. completion

15 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

The effect of diet and exercise on systemic inflammatory status

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov